According to the LEADER trial, the addition of the GLP-1 analog liraglutide to conventional treatment significantly reduced the incidence of cardiovascular end point events in patients with type 2 diabetes compared with the placebo group [137, 138]. Here, GLP1R is linked to type 2 diabetes mellitus.